BIODISTRIBUTION OF LIPOSOMAL AMPHOTERICIN-B (AMBISOME) AND AMPHOTERICIN B-DEOXYCHOLATE (FUNGIZONE) IN UNINFECTED IMMUNOCOMPETENT MICE AND LEUKOPENIC MICE INFECTED WITH CANDIDA-ALBICANS

被引:79
作者
VANETTEN, EWM
OTTELAMBILLION, M
VANVIANEN, W
TENKATE, MT
BAKKERWOUDENBERG, IAJM
机构
[1] Erasmus University Rotterdam, Department of Clinical Microbiology, Antimicrobial Therapy, 3000 DR Rotterdam
关键词
D O I
10.1093/jac/35.4.509
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The biodistribution of liposomal amphotericin B (L-AmB; AmBisome) and amphotericin B-desoxycholate were compared after a single injection of drug in uninfected immunocompetent mice and in leucopenic mice 6 h after inoculation with Candida albicans. Amphotericin B-desoxycholate was administered at the maximum tolerated dose (MTD) of 0.3 mg/kg whereas L-AmB was given at either 0.3 mg/kg or the MTD of 7 mg/kg. Amphotericin B (AmB) concentrations in the blood, liver, spleen, lungs and kidneys were determined by HPLC analysis at various intervals during the 48 h after administration. The biodistribution of both preparations of AmB followed similar patterns in both uninfected immunocompetent mice as well as those that were leucopenic and infected with C. albicans. Administration of L-AmB resulted in increased concentrations of drug in the blood, liver and spleen but decreased concentrations in the kidney and lung. Hepatosplenic uptake of L-AmB was highly dose dependent with 7 mg/kg resulting in a relatively prolonged blood circulation, Blood and tissues retained high AmB concentrations after administration of L-AmB at the MTD. By using radiolabelled L-AmB, it was found that the high AmB concentrations in blood represented liposome-associated AmB and that during circulation in blood slow release of AmB occurred.
引用
收藏
页码:509 / 519
页数:11
相关论文
共 24 条
[1]  
ADLERMOORE J, 1993, BONE MARROW TRANSPL, V12, pS146
[2]   TREATMENT OF MURINE CANDIDOSIS AND CRYPTOCOCCOSIS WITH A UNILAMELLAR LIPOSOMAL AMPHOTERICIN-B FORMULATION (AMBISOME) [J].
ADLERMOORE, JP ;
CHIANG, SM ;
SATORIUS, A ;
GUERRA, D ;
MCANDREWS, B ;
MCMANUS, EJ ;
PROFFITT, RT .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 28 :63-71
[3]   AMPHOTERICIN-B LIPID COMPLEX THERAPY OF EXPERIMENTAL FUNGAL-INFECTIONS IN MICE [J].
CLARK, JM ;
WHITNEY, RR ;
OLSEN, SJ ;
GEORGE, RJ ;
SWERDEL, MR ;
KUNSELMAN, L ;
BONNER, DP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (04) :615-621
[4]  
CLEMONS KV, 1993, J MED VET MYCOL, V31, P387
[5]   THERAPEUTIC EFFICACY OF A LIPOSOMAL FORMULATION OF AMPHOTERICIN-B (AMBISOME) AGAINST MURINE BLASTOMYCOSIS [J].
CLEMONS, KV ;
STEVENS, DA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 (03) :465-472
[6]  
DEMARIE S, 1994, J ANTIMICROB CHEMOTH, V33, P907
[7]   RELATIONSHIP OF PHARMACOKINETICS AND DRUG DISTRIBUTION IN TISSUE TO INCREASED SAFETY OF AMPHOTERICIN-B COLLOIDAL DISPERSION IN DOGS [J].
FIELDING, RM ;
SINGER, AW ;
WANG, LH ;
BABBAR, S ;
GUO, LSS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (02) :299-307
[8]   COMPARATIVE PHARMACOKINETICS OF AMPHOTERICIN-B AFTER ADMINISTRATION OF A NOVEL COLLOIDAL DELIVERY SYSTEM, ABCD, AND A CONVENTIONAL FORMULATION TO RATS [J].
FIELDING, RM ;
SMITH, PC ;
WANG, LH ;
PORTER, J ;
GUO, LSS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (06) :1208-1213
[9]   EFFICACY OF UNILAMELLAR LIPOSOMAL AMPHOTERICIN-B IN TREATMENT OF PULMONARY ASPERGILLOSIS IN PERSISTENTLY GRANULOCYTOPENIC RABBITS - THE POTENTIAL ROLE OF BRONCHOALVEOLAR D-MANNITOL AND SERUM GALACTOMANNAN AS MARKERS OF INFECTION [J].
FRANCIS, P ;
LEE, JW ;
HOFFMAN, A ;
PETER, J ;
FRANCESCONI, A ;
BACHER, J ;
SHELHAMER, J ;
PIZZO, PA ;
WALSH, TJ .
JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (02) :356-368
[10]  
GALLIS HA, 1990, REV INFECT DIS, V12, P308